Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Código da empresaALEC
Nome da EmpresaAlector Inc
Data de listagemFeb 07, 2019
CEORosenthal (Arnon)
Número de funcionários238
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 07
Endereço131 Oyster Point Blvd., Suite 600
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone14152315660
Sitehttps://alector.com
Código da empresaALEC
Data de listagemFeb 07, 2019
CEORosenthal (Arnon)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados